InvestorsHub Logo
Post# of 65082
Next 10
Followers 3
Posts 72
Boards Moderated 0
Alias Born 05/14/2014

Re: None

Friday, 12/08/2017 5:17:45 AM

Friday, December 08, 2017 5:17:45 AM

Post# of 65082
Wow. Sage Therapeutics (SAGE) rose 70% on Strong Phase 2 Results (to a market cap of $6.5B)after announcing strong top-line results from its Phase 2 clinical trial of SAGE-217, a treatment for moderate to severe major depressive disorder (MDD) in adults.

Axsome Therapeutics has a drug on Phase 3 trial for treatment resistant depression. Results first half of 2018.

2 more catalysts this month.
Do your DD.

Just saying ;)
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.